Merck Animal Health’s Innovax-ND-H5 Vaccine Gains the EC’s Marketing Authorization for Chickens
Shots:
- The EC has granted marketing authorization to the company’s Innovax-ND-H5 vaccine to address avian influenza virus strains of clade 2.3.4.4b in chickens
- The Innovax-ND-H5 is a single-dose vaccine given in ovo or subcutaneously at one day old to reduce mortality, symptoms and virus excretion from H5-type highly pathogenic Avian Influenza (HPAI)
- Furthermore, the vaccine produces immunity against Marek’s and Newcastle diseases plus can be administered in addition to its Rispens strain Marek’s disease vaccine, Nobilis Rismavac
Ref: Merck Animal Health | Image: Merck Animal Health
Related News:- Merck Animal Health to Feature Innovative Solutions Focusing Ruminant Health at the World Buiatrics Congress 2024
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
